JP2012521963A - 新規統合失調症治療用医薬組成物 - Google Patents

新規統合失調症治療用医薬組成物 Download PDF

Info

Publication number
JP2012521963A
JP2012521963A JP2011541012A JP2011541012A JP2012521963A JP 2012521963 A JP2012521963 A JP 2012521963A JP 2011541012 A JP2011541012 A JP 2011541012A JP 2011541012 A JP2011541012 A JP 2011541012A JP 2012521963 A JP2012521963 A JP 2012521963A
Authority
JP
Japan
Prior art keywords
lower alkyl
optionally substituted
aryl
compound
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011541012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521963A5 (OSRAM
Inventor
真司 ▲高▼橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JP2012521963A publication Critical patent/JP2012521963A/ja
Publication of JP2012521963A5 publication Critical patent/JP2012521963A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011541012A 2009-03-31 2010-03-30 新規統合失調症治療用医薬組成物 Withdrawn JP2012521963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2660962 2009-03-31
CA2660962A CA2660962A1 (en) 2009-03-31 2009-03-31 Novel pharmaceutical composition for treatment of schizophrenia
PCT/JP2010/056144 WO2010114163A1 (en) 2009-03-31 2010-03-30 Compositions comprising 2, 4, 6-triamino-1, 3, 5-triazine derivatives for treatment of schizophrenia

Publications (2)

Publication Number Publication Date
JP2012521963A true JP2012521963A (ja) 2012-09-20
JP2012521963A5 JP2012521963A5 (OSRAM) 2013-05-09

Family

ID=42269730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011541012A Withdrawn JP2012521963A (ja) 2009-03-31 2010-03-30 新規統合失調症治療用医薬組成物

Country Status (7)

Country Link
EP (1) EP2413940A1 (OSRAM)
JP (1) JP2012521963A (OSRAM)
KR (1) KR20120004488A (OSRAM)
CN (1) CN102378630A (OSRAM)
CA (1) CA2660962A1 (OSRAM)
TW (1) TW201035081A (OSRAM)
WO (1) WO2010114163A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103351348A (zh) * 2013-07-15 2013-10-16 黄河三角洲京博化工研究院有限公司 一种2-甲胺基嘧啶盐酸盐的合成方法
KR200492485Y1 (ko) 2016-02-16 2020-10-23 주식회사 마르시끄 일회용 마스카라

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1982799A (en) 1998-01-23 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
JP2010524434A (ja) * 2007-03-26 2010-07-22 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｋｃｎｈ２の統合失調症関連アイソフォームおよび抗精神病薬の開発

Also Published As

Publication number Publication date
EP2413940A1 (en) 2012-02-08
KR20120004488A (ko) 2012-01-12
TW201035081A (en) 2010-10-01
CN102378630A (zh) 2012-03-14
WO2010114163A1 (en) 2010-10-07
CA2660962A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
ES2761295T3 (es) Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula
CN105732591B (zh) 取代的哌嗪化合物及其使用方法和用途
WO2010092962A1 (ja) へテロ環誘導体
AU2013350819B9 (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia
JPWO2004011430A1 (ja) ナトリウムチャネル阻害剤
JP2020526557A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP2012521963A (ja) 新規統合失調症治療用医薬組成物
US20100256152A1 (en) Novel pharmaceutical composition for treatment of schizophrenia
JP2023549583A (ja) リアノジン受容体関連障害治療用薬剤
JP5673676B2 (ja) イミダゾ［１，２−ａ］ピリジン誘導体
JPWO2010137689A1 (ja) 注意欠陥／多動性障害新規予防用及び／又は治療用医薬組成物
US12138243B2 (en) Antiviral use of FABP4 modulating compounds
WO2014152869A2 (en) Benzyl urea derivatives for activating tgf-beta signaling
AU2009201338A1 (en) Novel pharmaceutical composition for treatment of schizophrenia
BRPI0901286A2 (pt) nova composição farmacêutica para o tratamento da esquizofrenia
CN117957229A (zh) 酪氨酸激酶抑制剂
US20250346572A1 (en) Non-acid inhibitors of inositol hexakisphosphate kinase (ip6k) and methods of use thereof
WO2023166351A1 (zh) 组胺h3受体抑制剂及其医药用途
US8252801B1 (en) Treatment of schizophrenia and related disorders
IL322808A (en) Quinoline derivatives used as kappa-opioid receptor agonists
HK40024430A (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclo-hexylamine for treating negative symptoms of schizophrenia
HK1212608B (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating primary negative symptoms of schizophrenia
NZ622331B2 (en) Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
NZ622331A (en) Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130325

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131121